Research programme: SMOC2 antibodies - Mediar Therapeutics
Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Mediar Therapeutics
- Class Antibodies; Antifibrotics
- Mechanism of Action SMOC2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis